GLENMARK - Glenmark Pharmaceuticals ltd Share Price

Name: Glenmark Pharmaceuticals (GLENMARK)
Brand: Glenmark Pharmaceuticals (GLENMARK)

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

GLENMARK

46/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹2266.40+40.60(+1.82%)

Market Closed as of Mar 11, 2026, 15:29 IST

Valuation
Market Cap	60.02 kCr
Price/Earnings (Trailing)	59.44
Price/Sales (Trailing)	3.7
EV/EBITDA	25.44
Price/Free Cashflow	-33.36
MarketCap/EBT	39.3
Enterprise Value	58.26 kCr

Fundamentals
Revenue (TTM)	16.22 kCr
Rev. Growth (Yr)	79.9%
Earnings (TTM)	1.01 kCr
Earnings Growth (Yr)	72.2%

Profitability
Operating Margin	22%
EBT Margin	9%
Return on Equity	10.54%
Return on Assets	5.31%
Free Cashflow Yield	-3%

Growth & Returns
Price Change 1W	-0.50%
Price Change 1M	8.5%
Price Change 6M	3.6%
Price Change 1Y	52.3%
3Y Cumulative Return	71.6%
5Y Cumulative Return	35.4%
7Y Cumulative Return	19.9%
10Y Cumulative Return	10.2%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	2.09 Cr
Cash Flow from Operations (TTM)	-827.6 Cr
Cash Flow from Financing (TTM)	787.04 Cr
Cash & Equivalents	2.65 kCr
Free Cash Flow (TTM)	-1.58 kCr
Free Cash Flow/Share (TTM)	-55.89

Balance Sheet
Total Assets	19 kCr
Total Liabilities	9.42 kCr
Shareholder Equity	9.58 kCr
Current Assets	11.45 kCr
Current Liabilities	6.96 kCr
Net PPE	3.4 kCr
Inventory	3.28 kCr
Goodwill	80.67 Cr

Capital Structure & Leverage
Debt Ratio	0.05
Debt/Equity	0.09
Interest Coverage	5.27
Interest/Cashflow Ops	-2.67

Dividend & Shareholder Returns
Dividend/Share (TTM)	5
Dividend Yield	0.24%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Technical Indicators
RSI (14d)	65.93
RSI (5d)	68.47
RSI (21d)	68.29
MACD Signal	Buy
Stochastic Oscillator Signal	Sell
SharesGuru Signal	Buy
RSI Signal	Hold
RSI5 Signal	Hold
RSI21 Signal	Hold
SMA 5 Signal	Buy
SMA 10 Signal	Buy
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.32 LCr	58.94 kCr	+5.60%	+11.50%	39.55	7.33	-	-
DRREDDY	Dr. Reddy's Lab	1.09 LCr	36.09 kCr	+5.10%	+14.40%	19.5	3.02	-	-
LUPIN	Lupin	1.07 LCr	26.49 kCr	+6.80%	+16.10%	23.04	4.04	-	-
CIPLA	Cipla	1.07 LCr	29.37 kCr	-0.40%	-9.60%	23.47	3.63	-	-
AUROPHARMA	Aurobindo Pharma	71.55 kCr	33.73 kCr	+1.60%	+10.50%	20.52	2.12	-	-

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	12.8%	13,322	11,813	12,990	12,305	10,944	10,641
Revenue From Operations	-	-	-	-	-	-	-
Other Income	-86.5%	114	840	317	167	50	160
Other Income	-	-	-	-	-	-	-
Total Income	6.2%	13,435	12,653	13,307	12,472	10,994	10,801
Total Income	-	-	-	-	-	-	-
Cost of Materials	-5%	3,001	3,158	3,594	3,279	3,138	2,541
Cost of Materials	-	-	-	-	-	-	-
Purchases of stock-in-trade	7.9%	1,566	1,451	1,268	1,118	750	1,029
Purchases of stock-in-trade	-	-	-	-	-	-	-
Employee Expense	5.4%	3,022	2,868	2,781	2,447	2,344	2,255
Employee Expense	-	-	-	-	-	-	-
Finance costs	-60%	207	516	350	298	353	377
Finance costs	-	-	-	-	-	-	-
Depreciation and Amortization	-16.5%	486	582	611	487	444	417
Depreciation and Amortization	-	-	-	-	-	-	-
Other expenses	7.8%	3,595	3,336	3,394	3,152	2,817	2,989
Other expenses	-	-	-	-	-	-	-
Total Expenses	-0.5%	11,663	11,716	11,673	10,769	9,656	9,737
Total Expenses	-	-	-	-	-	-	-
Profit Before exceptional items and Tax	89.2%	1,772	937	1,634	1,702	1,338	1,063
Profit Before exceptional items and Tax	-	-	-	-	-	-	-
Exceptional items before tax	58.6%	-372.82	-900.96	-765.85	-260.91	45	33
Total profit before tax	3894.3%	1,399	36	868	1,441	1,382	1,096
Total profit before tax	-	-	-	-	-	-	-
Current tax	-65.8%	382	1,116	567	547	498	396
Current tax	-	-	-	-	-	-	-
Deferred tax	-104.2%	-30.27	752	-75.85	-99.05	-85.75	-76.02
Deferred tax	-	-	-	-	-	-	-
Total tax	-81.2%	352	1,867	491	448	412	320
Total tax	-	-	-	-	-	-	-
Total profit (loss) for period	172.9%	1,047	-1,433.52	377	994	970	776
Total profit (loss) for period	-	-	-	-	-	-	-
Other comp. income net of taxes	194.7%	64	-65.55	154	77	87	-245.72
Other comp. income net of taxes	-	-	-	-	-	-	-
Total Comprehensive Income	174%	1,111	-1,499.08	531	1,070	1,057	530
Total Comprehensive Income	-	-	-	-	-	-	-
Earnings Per Share, Basic	166.6%	37.11	-53.22	10.53	33.37	34.38	27.5
Earnings Per Share, Basic	-	-	-	-	-	-	-
Earnings Per Share, Diluted	166.6%	37.1	-53.22	10.53	33.37	34.38	27.5
Earnings Per Share, Diluted	-	-	-	-	-	-	-

Description	(%) Q/Q	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024
Revenue From Operations	85.3%	6,047	3,264	3,256	3,388	3,434	3,244
Other Income	700%	201	26	12	31	39	31
Total Income	89.9%	6,248	3,291	3,268	3,419	3,473	3,276
Cost of Materials	-1.4%	722	732	795	746	774	686
Purchases of stock-in-trade	6.7%	620	581	345	418	443	360
Employee Expense	42.4%	1,086	763	737	788	787	710
Finance costs	14%	66	58	67	52	48	40
Depreciation and Amortization	8.5%	141	130	125	123	120	118
Other expenses	47.6%	1,337	906	870	915	975	835
Total Expenses	35.6%	3,895	2,872	2,887	2,962	3,001	2,813
Profit Before exceptional items and Tax	462.7%	2,353	419	381	456	473	462
Exceptional items before tax	-327.5%	-1,385.12	-323.23	-372.82	0	0	0
Total profit before tax	916.8%	967	96	7.97	456	473	462
Current tax	325%	460	109	-3.5	103	136	147
Deferred tax	-68.6%	-103.06	-60.71	7.09	5.24	-17.82	-24.79
Total tax	641.7%	357	49	3.59	108	118	122
Total profit (loss) for period	1223.9%	610	47	4.38	348	354	340
Other comp. income net of taxes	3%	104	101	258	-176.47	-22.4	5.49
Total Comprehensive Income	385.7%	715	148	262	172	332	346
Earnings Per Share, Basic	3025.8%	21.63	1.66	0.16	12.33	12.55	12.06
Earnings Per Share, Diluted	3024.2%	21.62	1.66	0.16	12.33	12.55	12.06

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	16.9%	9,226	7,891	8,221	8,142	7,568	6,713
Revenue From Operations	-	-	-	-	-	-	-
Other Income	-69.6%	356	1,168	986	615	396	607
Other Income	-	-	-	-	-	-	-
Total Income	5.8%	9,583	9,059	9,207	8,756	7,964	7,319
Total Income	-	-	-	-	-	-	-
Cost of Materials	-7%	2,781	2,990	3,036	2,993	2,678	2,252
Cost of Materials	-	-	-	-	-	-	-
Purchases of stock-in-trade	15.5%	373	323	391	482	316	365
Purchases of stock-in-trade	-	-	-	-	-	-	-
Employee Expense	11.8%	1,604	1,435	1,347	1,193	1,107	1,072
Employee Expense	-	-	-	-	-	-	-
Finance costs	-82.6%	49	277	207	236	266	256
Finance costs	-	-	-	-	-	-	-
Depreciation and Amortization	8.5%	219	202	184	160	151	139
Depreciation and Amortization	-	-	-	-	-	-	-
Other expenses	8.7%	2,180	2,005	2,006	1,802	1,571	1,670
Other expenses	-	-	-	-	-	-	-
Total Expenses	1.7%	7,250	7,129	7,139	6,849	6,094	5,803
Total Expenses	-	-	-	-	-	-	-
Profit Before exceptional items and Tax	20.9%	2,333	1,930	2,068	1,907	1,870	1,516
Profit Before exceptional items and Tax	-	-	-	-	-	-	-
Exceptional items before tax	-103.6%	-179.17	5,070	-495.87	430	74	19
Total profit before tax	-69.2%	2,154	7,001	1,572	2,337	1,944	1,535
Total profit before tax	-	-	-	-	-	-	-
Current tax	-70%	316	1,050	387	411	344	269
Current tax	-	-	-	-	-	-	-
Deferred tax	-71%	228	783	-23.83	-71.42	-49.31	-89.14
Deferred tax	-	-	-	-	-	-	-
Total tax	-70.4%	544	1,833	363	340	294	180
Total tax	-	-	-	-	-	-	-
Total profit (loss) for period	-68.9%	1,610	5,167	1,209	1,998	1,649	1,355
Total profit (loss) for period	-	-	-	-	-	-	-
Other comp. income net of taxes	-29.7%	-6.47	-4.76	0.63	1.6	2.48	-5.42
Other comp. income net of taxes	-	-	-	-	-	-	-
Total Comprehensive Income	-68.9%	1,604	5,163	1,209	1,999	1,652	1,349
Total Comprehensive Income	-	-	-	-	-	-	-
Earnings Per Share, Basic	-69.2%	57.07	183.13	42.84	70.8	58.46	48
Earnings Per Share, Basic	-	-	-	-	-	-	-
Earnings Per Share, Diluted	-69.2%	57.07	183.12	42.84	70.8	58.46	48
Earnings Per Share, Diluted	-	-	-	-	-	-	-

Description	(%) Q/Q	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024
Revenue From Operations	-35.8%	1,539	2,395	2,009	2,251	2,636	2,330
Other Income	319.1%	286	69	88	129	83	56
Total Income	-26%	1,824	2,464	2,098	2,380	2,719	2,385
Cost of Materials	-1.3%	668	677	696	715	723	648
Purchases of stock-in-trade	-8.2%	91	99	91	89	104	89
Employee Expense	11.3%	454	408	383	428	408	384
Finance costs	57.1%	23	15	13	8.46	12	15
Depreciation and Amortization	1.8%	59	58	56	55	55	53
Other expenses	12.4%	607	540	500	544	615	520
Total Expenses	3.4%	1,799	1,740	1,738	1,821	1,924	1,767
Profit Before exceptional items and Tax	-96.7%	25	724	360	559	795	618
Exceptional items before tax	-187.7%	-931.79	-323.23	-179.17	0	0	0
Total profit before tax	-326.8%	-906.37	401	181	559	795	618
Current tax	-203.1%	-70.17	70	-25.62	95	138	108
Deferred tax	-42508.7%	-97	0.77	59	50	62	57
Total tax	-340.3%	-167.18	71	33	146	200	165
Total profit (loss) for period	-325%	-739.19	330	148	414	595	454
Other comp. income net of taxes	-920.9%	-14.62	-0.53	-3	-0.53	-2.12	-0.81
Total Comprehensive Income	-329.4%	-753.81	330	145	413	593	453
Earnings Per Share, Basic	-354.1%	-26.19	11.7	5.24	14.66	21.09	16.08
Earnings Per Share, Diluted	-354.1%	-26.19	11.7	5.24	14.66	21.09	16.08

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	58%	2,647	1,676	1,819	1,658	1,123	1,443
Total current financial assets	31.7%	6,731	5,110	4,904	3,691	4,550	5,742
Inventories	8.3%	3,281	3,029	2,840	2,513	2,650	2,978
Current tax assets	24.6%	1,441	1,157	0	0	0	0
Total current assets	23.2%	11,453	9,295	9,033	7,428	8,643	9,874
Property, plant and equipment	2.4%	3,399	3,319	3,155	3,118	3,104	3,904
Capital work-in-progress	28.3%	695	542	395	419	1,221	1,115
Goodwill	15.9%	81	70	70	67	69	74
Non-current investments	-25.5%	42	56	45	790	45	45
Total non-current financial assets	-9.4%	117	129	115	860	78	85
Total non-current assets	11.8%	7,549	6,754	6,202	6,931	8,739	9,498
Total assets	18.4%	19,002	16,050	15,235	14,359	20,006	19,372
Borrowings, non-current	3.9%	533	513	0	0	3,877	3,852
Total non-current financial liabilities	25.3%	1,472	1,175	604	691	4,431	4,443
Total non-current liabilities	99.7%	2,461	1,233	605	692	4,433	4,487
Borrowings, current	-78.7%	359	1,681	1,562	991	1,044	496
Total current financial liabilities	-4%	4,936	5,144	4,984	4,642	4,313	4,238
Provisions, current	12.6%	671	596	773	641	531	508
Current tax liabilities	2214.8%	626	28	166	291	123	106
Total current liabilities	16.6%	6,960	5,967	6,185	5,819	5,290	5,046
Total liabilities	30.8%	9,420	7,200	6,790	6,511	10,271	9,532
Equity share capital	0%	28	28	28	28	28	28
Non controlling interest	10.9%	-0.22	-0.37	-0.16	-0.38	409	365
Total equity	8.3%	9,582	8,849	8,446	7,848	9,736	9,839
Total equity and liabilities	18.4%	19,002	16,050	15,235	14,359	20,006	19,372

Category	GLENMARK	Pharmaceuticals
PE	59.44	34.64
PS	3.70	4.78
Growth	23.5 %	10.8 %

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-35.4%	85	131	973	128	30	93
Total current financial assets	8.2%	2,923	2,702	4,410	2,744	2,697	2,687
Inventories	1.9%	1,395	1,369	1,269	1,143	1,188	1,090
Total current assets	8%	5,158	4,778	6,394	4,681	4,736	4,385
Property, plant and equipment	7.3%	1,782	1,661	1,608	1,539	1,491	1,489
Capital work-in-progress	39.2%	168	121	170	176	165	159
Investment property	-100.8%	0	124	0	0	0	0
Non-current investments	0%	15,202	15,195	15,183	12,965	12,226	10,334
Loans, non-current	-7.2%	5,340	5,754	3,788	7,506	5,676	6,874
Total non-current financial assets	-1.9%	20,588	20,995	19,015	20,515	17,927	17,231
Total non-current assets	-1.2%	22,985	23,256	21,130	22,733	20,776	20,201
Total assets	1.3%	28,384	28,033	27,523	27,414	25,514	24,586
Borrowings, non-current	-	0	0	0	0	2,671	2,661
Total non-current financial liabilities	126.8%	509	225	157	154	2,866	3,067
Total non-current liabilities	80.1%	509	283	157	154	2,866	3,067
Borrowings, current	-48.7%	359	699	318	657	695	496
Total current financial liabilities	23.4%	3,729	3,023	3,099	3,860	3,867	3,434
Provisions, current	1.6%	128	126	117	115	105	97
Current tax liabilities	-	21	0	119	240	78	66
Total current liabilities	20.8%	3,921	3,246	3,420	4,289	4,271	3,642
Total liabilities	25.9%	4,444	3,529	3,578	4,444	7,137	6,708
Equity share capital	0%	28	28	28	28	28	28
Total equity	-2.3%	23,940	24,504	23,946	22,971	18,377	17,877
Total equity and liabilities	1.3%	28,384	28,033	27,523	27,414	25,514	24,586

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-60.1%	207	517	350	298	-	-
Change in inventories	12.2%	-450.81	-513.86	-375.17	-203.42	-	-
Depreciation	-23%	486	631	611	487	-	-
Unrealised forex losses/gains	79.6%	-69.06	-342.59	-286.16	-227.41	-	-
Dividend income	-	0	0	0.35	0.35	-	-
Adjustments for interest income	168.8%	44	17	23	9.44	-	-
Share-based payments	-356.8%	-9.17	4.96	6.77	7.92	-	-
Net Cashflows from Operations	-119%	-147.47	782	1,266	1,667	-	-
Income taxes paid (refund)	-35.1%	680	1,047	641	558	-	-
Net Cashflows From Operating Activities	-211%	-827.6	-265.44	625	1,109	-	-
Proceeds from sales of PPE	-	0	0	57	1.58	-	-
Purchase of property, plant and equipment	-16.5%	750	898	608	790	-	-
Proceeds from sales of investment property	31.5%	2.42	2.08	0	0	-	-
Proceeds from sales of long-term assets	-	0	0	5	30	-	-
Purchase of other long-term assets	-106.7%	0	16	6.01	40	-	-
Dividends received	-	0.01	0	0.35	0.35	-	-
Interest received	156.2%	42	17	23	9.32	-	-
Other inflows (outflows) of cash	84.6%	-28.61	-191.88	-0.07	25	-	-
Net Cashflows From Investing Activities	-100%	2.09	4,369	-528.49	-333.28	-	-
Proceeds from issuing shares	-600%	0	1.2	0	0	-	-
Proceeds from issuing other equity instruments	-	0	0	0	1,012	-	-
Payments to acquire or redeem entity's shares	-	30	0	0	0	-	-
Proceeds from borrowings	179.2%	1,341	481	1,163	2,130	-	-
Repayments of borrowings	-96.2%	141	3,649	686	3,218	-	-
Payments of lease liabilities	17.5%	122	104	107	101	-	-
Dividends paid	-41%	70	118	137	93	-	-
Interest paid	-63.2%	191	517	312	251	-	-
Net Cashflows from Financing Activities	120.1%	787	-3,906.13	-77.46	-520.49	-	-
Effect of exchange rate on cash eq.	223.5%	56	18	13	18	-	-
Net change in cash and cash eq.	-92.5%	17	215	32	272	-	-

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-82.6%	49	277	207	236	-	-
Change in inventories	-53.3%	-226.62	-147.52	-138.55	-189.28	-	-
Depreciation	8.5%	219	202	184	160	-	-
Unrealised forex losses/gains	31.7%	-118.06	-173.4	-279.51	-154.87	-	-
Dividend income	-100.4%	0.01	228	320	107	-	-
Adjustments for interest income	17.9%	205	174	184	339	-	-
Share-based payments	-	0	0	0.02	0.23	-	-
Net Cashflows from Operations	212.3%	1,172	376	1,890	1,607	-	-
Income taxes paid (refund)	-33.1%	583	871	416	391	-	-
Net Cashflows From Operating Activities	218.4%	589	-495.45	1,474	1,216	-	-
Proceeds from sales of PPE	172%	1.36	0.5	317	0.54	-	-
Purchase of property, plant and equipment	75.3%	341	195	190	163	-	-
Proceeds from sales of long-term assets	-86.3%	745	5,450	5	30	-	-
Purchase of other long-term assets	36.6%	12	9.05	3.12	68	-	-
Dividends received	-100.4%	0.01	228	320	107	-	-
Interest received	-27.8%	201	278	313	153	-	-
Other inflows (outflows) of cash	5.3%	-0.07	-0.13	-0.11	0.08	-	-
Net Cashflows From Investing Activities	-115.3%	-489.52	3,197	-431.47	-896.92	-	-
Proceeds from changes in ownership interests in subsidiaries	102.5%	59	-2,299.18	0	0	-	-
Proceeds from issuing shares	-600%	0	1.2	0	0	-	-
Proceeds from borrowings	-	0	0	0	1,988	-	-
Repayments of borrowings	-	0	0	686	1,998	-	-
Payments of lease liabilities	11.4%	40	36	32	25	-	-
Dividends paid	0%	70	70	70	71	-	-
Interest paid	-83.5%	44	262	190	200	-	-
Net Cashflows from Financing Activities	96.4%	-95.41	-2,666.45	-978.5	-305.12	-	-
Effect of exchange rate on cash eq.	-35.3%	-0.38	-0.02	-0.05	-0.1	-	-
Net change in cash and cash eq.	-92.7%	3.49	35	64	14	-	-

GLENMARK - Glenmark Pharmaceuticals ltd Share Price

GLENMARK

GLENMARK - Glenmark Pharmaceuticals ltd Share Price

GLENMARK

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

GLENMARK

Investor Care

Financial Health

Technical Indicators

The Bad News

The Good News

Updates from Glenmark Pharmaceuticals

What does Glenmark Pharmaceuticals ltd do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

GLENMARK

Investor Care

Financial Health

Technical Indicators

The Bad News

The Good News

Updates from Glenmark Pharmaceuticals

What does Glenmark Pharmaceuticals ltd do?

Important Disclosure & Data Context